SpectraCure publishes memorandum for rights issue of SEK 34 million
The subscription period runs from July 21 to August 4. Each unit contains one share and one warrant.
See the latest news and media coverage for SpectraCure. We track all announcements, press releases, and industry mentions in real time, all in one place.
Developer of photodynamic therapy systems for solid tumors
spectracure.comLast updated
In short: SpectraCure initiated a 34 MSEK rights issue to fund clinical trials and phase 3 preparations after reporting narrow losses in early 2026.
The subscription period runs from July 21 to August 4. Each unit contains one share and one warrant.
The meeting decided on changes to the articles of association, capital reduction, and rights issue.
The issue aims to finance clinical studies and prepare for phase 3.
The annual general meeting adopted the income statement, granted discharge from liability, re-elected the board, decided on no dividend, authorization for share issue, and guidelines for remuneration.
The medical technology company SpectraCure has released the memorandum for its rights issue of SEK 34 million and Emissionsguiden raises a new flag for insufficient information.
The medical technology company SpectraCure is carrying out a rights issue that could bring the company 34 million SEK before costs. The Emission Guide raises four flags.
The medical technology company Spectracure, listed on the Nasdaq First North trading platform, reports a net result of -6.1 million kronor for the...
The research company Spectracure has decided to apply for permission to initiate a clinical study for primary localized prostate cancer. This appears from a press release.The board and management have during...
Track SpectraCure and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.